REMARKS

In response to the Notice to File Missing Parts, Applicants submit herewith a the required Reply, including substitute drawings, a copy of the sequence listing in computer readable format, and a statement that the sequence listing in computer readable format is identical to the written sequence listing and contains no new matter. Further details regarding this filing are set out below.

Substitute Drawings

Applicants submit herewith replacement drawings from which the excessive text has been removed. Accordingly, the specification has been amended to include text corresponding to the text that was removed from the Figure captions. A marked up copy of the drawings, showing the changes made thereto is also attached.

Amendments to the Specification

As stated above, because the drawings were amended to remove excessive text, the specification has been amended to include text corresponding to the text that was removed from the Figure captions.

Sequence Listing

As required, a substitute Sequence Listing containing the six amino acid sequences described in the original specification is submitted herewith and is to be appended to the specification. A Sequence Listing Statement under 37 CFR 1.821(f) and (g) is also attached hereto, along with a computer readable copy of the same (3.5" diskette). A Statement that the sequence listing in computer readable format is identical to the written sequence listing that was present in the originally filed specification and contains no new matter is also enclosed.

Respectfully submitted,

Marcella D. Watkins Reg. No. 36,962

CONLEY ROSE, P.C.

P. O. Box 3267

Houston, Texas 77253-3267

(713) 238-8000

ATTORNEY FOR APPLICANT








Figure 1A: Migration of Human aortic endothelial cells in response to IGD tripeptide, capped IGD tripeptide. A dose dependent effect was observed with the optimal concentration being 100 μM for the uncapped peptide. However, with the capped peptide better migration compared to the uncapped peptide was observed at a 10-fold lower concentration. The respective scramble peptides showed fewer number of cells migrating (data not shown)



Figure 1B: Migration of human aortic smooth muscle cells in response to the tripeptide



BEST AVAILABLE COPY





Migration of Endothelial Cells




Figure 1C: This figure shows the migration of endothelial cells in a modified Boyden chamber assay in response to various treatments. Both IGD and GGIGDGG cause increased migratory response compared to either the negative control or the corresponding resemble peptides.






Figure 2

Proliferation of Human aortic endothelial cells in response to treatment with IGD tripeptide, the capped IGD tripeptide, and capped and uncapped scramble tripeptide, at two different concentrations. It can be seen that with the capped tripeptide the proliferative response was nearly twice as that of the uncapped tripeptide. In either case the scramble peptides showed a significantly lower response than the active pentides.







Figure 3A: Quail CAM assay showing increase in blood vessels in response to the peptide and the capped peptide compared to the respective scramble peptides. Determined here is as a percent change over negative control, the negative being set at 100%. It can be seen that the capped peptide was better that the uncapped peptide at equivalent concentrations

Sest available copy




Quail CAM Assay with Peptides



1%Povidone (negative control)



100µM GGDIGGG



100µM GGIGDGG

Figure 3B: Angiogenic response of the capped IGD-motif in the quail CAM assay. The vessel density in 7 days old quail embryos treated with the capped IGD motif (GGIGDGG) resulted in increased vessel density compared to either the carrier alone (povidone) or the security poplide (GCDICGG) treatment

BEST AVAILABLE COPY